News Website

The Tonies Bluey collection is now available at Target and the Tonies website - Mashable

The Tonies Bluey collection is now available at Target and the Tonies website Mashable

Published: July 22, 2026, 5:52 p.m.

Read Full Article

Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper - Seoul Economic Daily

Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper Seoul Economic Daily

Published: July 16, 2026, 5:33 a.m.

Read Full Article

Oriva: Targeting the endometriosis trifecta - biocentury.com

Oriva: Targeting the endometriosis trifecta biocentury.com

Published: July 16, 2026, 12:14 a.m.

Read Full Article

Oriva: Targeting the endometriosis trifecta - BioCentury

Oriva: Targeting the endometriosis trifecta BioCentury

Published: July 16, 2026, 12:14 a.m.

Read Full Article

New reporting tool targets maternal-fetal teams as pregnancy complexity rises - FemTech World

New reporting tool targets maternal-fetal teams as pregnancy complexity rises FemTech World

Published: July 9, 2026, 1:46 p.m.

Read Full Article

Xella targets to fill the gaps in women’s diagnostics with AI - Longevity.Technology

Xella targets to fill the gaps in women’s diagnostics with AI Longevity.Technology

Published: June 29, 2026, 5:01 p.m.

Read Full Article

H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com South Africa

H.C. Wainwright raises Absci stock price target on trial data By Investing.com Investing.com South Africa

Published: June 25, 2026, 5:39 p.m.

Read Full Article

H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com Australia

H.C. Wainwright raises Absci stock price target on trial data By Investing.com Investing.com Australia

Published: June 25, 2026, 5:15 p.m.

Read Full Article

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com

Published: June 24, 2026, 11:25 a.m.

Read Full Article

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times

Published: June 24, 2026, 10:48 a.m.

Read Full Article

Latest Articles

The Tonies Bluey collection is now available at Target and the Tonies website - Mashable

Onconic's Nesuparib Targets 26 Trillion Won Endometrial Cancer Market, Backed by SCI Paper - Seoul Economic Daily

Oriva: Targeting the endometriosis trifecta - biocentury.com

Oriva: Targeting the endometriosis trifecta - BioCentury

New reporting tool targets maternal-fetal teams as pregnancy complexity rises - FemTech World

Xella targets to fill the gaps in women’s diagnostics with AI - Longevity.Technology

H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com South Africa

H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com Australia

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times

Subscribe to Our Newsletter